AIM ImmunoTech Inc. (NYSE:AIM - Get Free Report) shares traded down 15.5% during trading on Wednesday . The stock traded as low as $8.20 and last traded at $8.58. 6,352 shares traded hands during trading, a decline of 99% from the average session volume of 571,431 shares. The stock had previously closed at $10.15.
AIM ImmunoTech Trading Up 11.0%
The company has a debt-to-equity ratio of 0.05, a current ratio of 0.75 and a quick ratio of 0.75. The stock has a 50-day moving average price of $9.13 and a two-hundred day moving average price of $14.16. The stock has a market cap of $665.79 million, a PE ratio of -19.60 and a beta of 0.76.
About AIM ImmunoTech
(
Get Free Report)
AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).
Featured Articles
Before you consider AIM ImmunoTech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AIM ImmunoTech wasn't on the list.
While AIM ImmunoTech currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
